Opinion|Videos|July 16, 2024
Perspectives on Shared Decision-Making in the Treatment of CLL
Bita Fakhri, MD, MPH, discusses the importance of patient involvement in the shared decision-making process to individualize treatment and improve outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Examine the importance of patient preferences and patient involvement in the shared decision-making process to individualize treatment and improve outcomes.
- How do you assess and incorporate patient preferences into treatment selection?
- What insights/implications do data recently presented at EHA 2023 offer?
Advertisement
Related to this article
Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses CLL17 trial data, resistance mechanisms, and emerging BTK degraders and bispecifics in CLL.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Alembic's generic venetoclax, therapeutically equivalent to Venclexta, received final FDA approval for CLL/SLL and newly diagnosed AML.
Advertisement
Advertisement
Trending on OncLive
1
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
2
Dr Levy on Where Iza-Bren May Fit Following Osimertinib In EGFR-Mutated NSCLC
3
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
4
Dr Levy on How the EGFR-Targeted Therapy Landscape Has Evolved in NSCLC
5